Evidence map›Paper›PMID 35066756›Full record

ReviewPituitary2022

Opioids and pituitary function: expert opinion.

Mônica R Gadelha, Niki Karavitaki, Jeffrey Fudin, Jeffrey J Bettinger, Hershel Raff, Anat Ben-Shlomo

Open access · greenAbstract readReview
PubMed Publisher
In one paragraph

Review in Pituitary, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Pitfalls in the lab assessment of hypopituitarism.Reviews in endocrine & metabolic disorders · 2024
    Review
  5. Diagnosing and treating the elderly individual with hypopituitarism.Reviews in endocrine & metabolic disorders · 2024
    Review
  6. Iatrogenic adrenal insufficiency in adults.Nature reviews. Endocrinology · 2024
    Review
  7. Article
  8. Review
  9. A Closer Look at Opioid-Induced Adrenal Insufficiency: A Narrative Review.International journal of molecular sciences · 2023
    Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 6 institutions in 3 countries.

Mônica R GadelhaEndocrine Unit and Neuroendocrinology Research Center, Medical School and Hospital Universitário Clementino Fraga Filho - Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Niki KaravitakiInstitute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.ORCID http://orcid.org/0000-0002-4696-0643
Jeffrey FudinPresident, Remitigate Therapeutics, Delmar, NY, USA.
Jeffrey J BettingerPain Management and Addiction Medicine, Saratoga Hospital Medical Group, Saratoga Springs, NY, USA.
Hershel RaffDivision of Endocrinology and Molecular Medicine, Departments of Medicine, Surgery, and Physiology, Medical College of Wisconsin, Milwaukee, WI, USA. hraff@mcw.edu.ORCID http://orcid.org/0000-0002-5128-8476
Anat Ben-ShlomoPituitary Center, Division of Endocrinology, Diabetes and Metabolism, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Cedars-Sinai Medical Center · USMedical College of Wisconsin · USSaratoga Hospital · USUniversidade Federal do Rio de Janeiro · BRUniversity Hospitals Birmingham NHS Foundation Trust · GBWestern New England University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeOpioids are highly addictive potent analgesics and anti-allodynics whose use has dramatically increased in recent decades. The precipitous rise in opioid dependency and opioid use disorder is an important public health challenge given the risks for severely adverse health outcomes. The long-term opioid impact on hypothalamic-pituitary axes is particularly underappreciated among both endocrinologists and primary care physicians. We review the effects of opioids on hypothalamic-pituitary-target gland function and their implications for clinical practice.

methodsExperts in hypothalamic-pituitary disorders and opioid pharmacology reviewed recently published literature and considered strategies for diagnosing and managing these opioid-induced endocrine effects.

resultsOpioid suppression of hypothalamic-pituitary axes can lead to hypogonadotropic hypogonadism, central adrenal insufficiency, and hyperprolactinemia. These important clinical manifestations are often under-estimated, poorly evaluated, and typically either untreated or not optimally managed. Data on biochemical testing for diagnosis and on the effect of hormone replacement in these patients is limited and prospective randomized controlled studies for guiding clinical practice are lacking.

conclusionsPatients should be informed about risks for hypogonadism, adrenal insufficiency, and hyperprolactinemia, and encouraged to report associated symptoms. Based on currently available evidence, we recommend clinical and biochemical evaluation for potential central adrenal insufficiency, central hypogonadism, and/or hyperprolactinemia in patients chronically treated with opioids as well as the use of current expert guidelines for the diagnosis and treatment of these conditions.

Indexed as

HyperprolactinemiaHypogonadismAnalgesics, OpioidHumansProspective StudiesAnalgesics, OpioidAdrenal insufficiencyHyperprolactinemiaHypogonadismHypopituitarismOpioids

Identifiers

PMID35066756
OpenAlexW4206961005

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.